Remove Antibody Remove Gene Expression Remove Protein
article thumbnail

US FDA grants Fast Track status for Avidity’s AOC 1020 to treat FSHD

Pharmaceutical Technology

AOC 1020 has been designed for the treatment of the underlying cause of FSHD, which is caused by the abnormal expression of a gene known as double homeobox 4 or DUX4. Avidity Biosciences’ AOC 1020 is intended to reduce the DUX4 mRNA and DUX4 protein expression in muscles in these patients.

article thumbnail

Blood vessels produce growth factor that promotes metastases

The Pharma Data

In mice, an antibody directed against this factor was able to slow the growth of metastatic tumors.Blood vessels produce growth factor that promotes metastases. ” With a particular focus on the lung, the researchers performed global gene expression analyses of the metastatic niche.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading innovators in transcription factors for genetically modified cells for the pharmaceutical industry

Pharmaceutical Technology

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130
article thumbnail

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.

RNA 40
article thumbnail

The 4 Biggest Cancer Biotech Acquisitions of 2021 So Far

XTalks

The biotech acquisition will also see Takeda getting Maverick’s TAK-280 (MVC-280), an immunotherapy designed to treat patients with B7H3-expressing solid tumors which is expected to enter the clinic later this year. The biotech acquisition deal includes Five Prime’s prime asset bemarituzumab, which is a first-in-class anti-FGFR2b antibody.

article thumbnail

Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication

The Pharma Data

HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. Reactivation of hepatitis B virus infection was reported in 1% of patients in clinical trials.

article thumbnail

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

Delveinsight

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. Omega’s platform is designed to adjust gene expression to healthy levels rather than switching genes on and off.

Genome 52